.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Farmers Insurance
Johnson and Johnson
Express Scripts
Queensland Health
Cerilliant
QuintilesIMS
Daiichi Sankyo
Colorcon
Healthtrust

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 074172

« Back to Dashboard

NDA 074172 describes NADOLOL, which is a drug marketed by Amneal Pharms Co, Invagen Pharms, Ivax Sub Teva Pharms, Lupin Ltd, Mylan, Orion Corp Orion, Sandoz, Teva Pharms, Zydus Pharms Usa Inc, and Impax Labs, and is included in twelve NDAs. It is available from seventeen suppliers. Additional details are available on the NADOLOL profile page.

The generic ingredient in NADOLOL is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.

Summary for 074172

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 074172

Mechanism of ActionAdrenergic beta-Antagonists

Suppliers and Packaging for NDA: 074172

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NADOLOL nadolol TABLET;ORAL 074172 ANDA Mylan Pharmaceuticals Inc. 0378-0028 0378-0028-01 100 TABLET in 1 BOTTLE (0378-0028-01)
NADOLOL nadolol TABLET;ORAL 074172 ANDA Mylan Pharmaceuticals Inc. 0378-1132 0378-1132-01 100 TABLET in 1 BOTTLE (0378-1132-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Oct 31, 1993TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Oct 31, 1993TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength80MG
Approval Date:Oct 31, 1993TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Dow
McKesson
Baxter
Covington
Novartis
Colorcon
Mallinckrodt
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot